Literature DB >> 29891522

Clinical Impact of Local Progression in Pancreatic Cancer.

Nicholas Cardillo, Daniel M Seible, Katherine E Fero, Andrew R Bruggeman, Reith R Sarkar, Alexa Azuara, Daniel R Simpson, James D Murphy.   

Abstract

Background: The high prevalence of distant metastatic disease among patients with pancreatic cancer often draws attention away from the local pancreatic tumor. This study aimed to define the complications and hospitalizations from local versus distant disease progression among a retrospective cohort of patients with pancreatic cancer.
Methods: Records of 298 cases of pancreatic cancer treated at a single institution from 2004 through 2015 were retrospectively reviewed, and cancer-related symptoms and complications requiring hospitalization were recorded. Hospitalizations related to pancreatic cancer were attributed to either local or distant progression. Cumulative incidence analyses were used to estimate the incidence of hospitalization, and multivariable Fine-Gray regression models were used to identify factors predictive of hospitalizations.
Results: The 1-year cumulative incidences of hospitalization due to local versus distant disease progression were 31% and 24%, respectively. Among 509 recorded hospitalizations, leading local etiologies included cholangitis (10%), biliary obstruction (7%), local procedure complication (7%), and gastrointestinal bleeding (7%). On multivariable analysis, significant predictors of hospitalization from local progression included unresectable disease (subdistribution hazard ratio [SDHR], 2.42; P<.01), black race (SDHR, 3.34; P<.01), younger age (SDHR, 1.02 per year; P=.01), tumor in the pancreatic head (SDHR, 2.19; P<.01), and larger tumor size (SDHR, 1.13 per centimeter; P=.02). Most patients who died in the hospital from pancreatic cancer (56%) were admitted for complications of local disease progression. Conclusions: Patients with pancreatic cancer experience significant complications of local tumor progression. Although distant metastatic progression represents a hallmark of pancreatic cancer, future research should also focus on improving local therapies.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2018        PMID: 29891522     DOI: 10.6004/jnccn.2018.7013

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  8 in total

1.  High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.

Authors:  Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection.

Authors:  Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.

Authors:  Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2022-03-17

4.  Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?

Authors:  Colin S Hill; Sarah Han-Oh; Zhi Cheng; Ken Kang-Hsin Wang; Jeffrey J Meyer; Joseph M Herman; Amol K Narang
Journal:  Radiat Oncol       Date:  2021-03-19       Impact factor: 3.481

5.  High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.

Authors:  Colin Hill; Shuchi Sehgal; Wei Fu; Chen Hu; Abhinav Reddy; Elizabeth Thompson; Amy Hacker-Prietz; Dung Le; Ana De Jesus-Acosta; Valerie Lee; Lei Zheng; Daniel A Laheru; William Burns; Matthew Weiss; Christopher Wolfgang; Jin He; Joseph M Herman; Jeffrey Meyer; Amol Narang
Journal:  Cancer Med       Date:  2022-02-10       Impact factor: 4.452

6.  Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer.

Authors:  Shalini Moningi; Xiudong Lei; Penny Fang; Cullen M Taniguchi; Emma B Holliday; Eugene J Koay; Albert C Koong; Ethan B Ludmir; Bruce D Minsky; Prajnan Das; Sharon H Giordano; Grace L Smith
Journal:  Clin Transl Radiat Oncol       Date:  2022-04-19

Review 7.  Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions.

Authors:  William A Hall; Christina Small; Eric Paulson; Eugene J Koay; Christopher Crane; Martijn Intven; Lois A Daamen; Gert J Meijer; Hanne D Heerkens; Michael Bassetti; Stephen A Rosenberg; Katharine Aitken; Sten Myrehaug; Laura A Dawson; Percy Lee; Cihan Gani; Michael David Chuong; Parag J Parikh; Beth A Erickson
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 5.738

Review 8.  Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature.

Authors:  Abhinav V Reddy; Shuchi Sehgal; Colin S Hill; Lei Zheng; Jin He; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  Curr Oncol       Date:  2022-01-11       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.